(Q44216575)

30 November 2017

title

Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates (English)

1 reference

30 November 2017

author

Guillermo Quindós Andrés

6

1 reference

30 November 2017

Carrillo-Muñoz AJ

1

1 reference

30 November 2017

Brió S

2

1 reference

30 November 2017

Alonso R

3

1 reference

30 November 2017

del Valle O

4

1 reference

30 November 2017

Santos P

5

1 reference

30 November 2017

publication date

1 November 2002

1 reference

International Journal of Antimicrobial Agents

30 November 2017

published in

1 reference

30 November 2017

volume

20

1 reference

30 November 2017

issue

5

1 reference

30 November 2017

page(s)

375-379

1 reference

Overview of medically important antifungal azole derivatives

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

Ciclopirox olamine: A hydroxypyridone antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

The hydroxypyridones: a class of antimycotics of its own.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

Evaluation of fungicidal action in vitro and in a skin model considering the influence of penetration kinetics of various standard antimycotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

In vitro activity of ME1401, a new antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

Tablet sensitivity testing on pathogenic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp..

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

In-vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

Detection of fluconazole-resistant Candida strains by a disc diffusion screening test

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900206-6

7 January 2021

10.1016/S0924-8579(02)00206-6

Identifiers

DOI

1 reference

30 November 2017

1 reference